Keyword: Domain Associates
The series C tees Milestone up to test its intranasal calcium channel blocker etripamil in patients with paroxysmal supraventricular tachycardia.
Iterum has completed a $65 million series B to equip it to take its antibiotic sulopenem through phase 3.
Longwood Fund and Domain Associates have led a $19.15 million funding round for newco Axial Biotherapeutics with the aim of creating new treatments for an array of CNS disorders by harnessing the gut microbiome.
Evoke Pharma saw its shares nose-dive by more 75% after it disclosed that a Phase III study for its nasal formulation of metoclopramide failed to meet its primary endpoint.